[Elective termination of respiratory therapy in amyotrophic lateral sclerosis].
Autor: | Meyer T; Neurologische Klinik und Poliklinik, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, Berlin, Germany. thomas.meyer@charite.de, Dullinger JS, Münch C, Keil JP, Hempel E, Rosseau S, Borisow N, Linke P |
---|---|
Jazyk: | němčina |
Zdroj: | Der Nervenarzt [Nervenarzt] 2008 Jun; Vol. 79 (6), pp. 684-90. |
DOI: | 10.1007/s00115-008-2439-9 |
Abstrakt: | Background: Due to the growing use of artificial respiration in amyotrophic lateral sclerosis (ALS), physicians are increasingly confronted with patients seeking discontinuation of therapy. Yet there are few systematic investigations of the withdrawal of ventilation therapy. Patients and Methods: In a retrospective investigation of nine German ALS patients, clinical data were recorded from the discontinuation of noninvasive ventilation (n=4) and mechanical ventilation (n=5). Results: In cases of residual spontaneous breathing, intensified symptom control of dyspnea and anxiety was possible with intravenous morphine sulfate at a low dose rate (10 mg/h) but high cumulative dose (185-380 mg). The terminal phase after removing the mask was protracted (22:10 h to 28:00 h). In cases of minimal or absent spontaneous breathing the disconnection was realized in deep sedation, which required a moderate total dose of morphine sulfate (120 mg) but a high dosage rate (up to 300 mg/h). The terminal phase in deep sedation was short (15-80 min). Conclusion: The elective termination of ventilation requires differentiated pharmacologic palliative care. More controlled studies are required in order to establish evidence-based guidelines for the termination of ventilation. |
Databáze: | MEDLINE |
Externí odkaz: |